Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk files annual report with the SEC
07:36am, Wednesday, 05'th Feb 2025
Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission (SEC), incorporating b
Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double
06:20am, Wednesday, 05'th Feb 2025
Novo Nordisk's (NVO) U.S.-listed shares are rising 4% in premarket trading Wednesday after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projec
Novo Nordisk says it's not immune to potential Trump tariffs, but business is well-positioned
05:54am, Wednesday, 05'th Feb 2025
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, its chief executive said on Wednesday, but it is confident its business is
Novo Nordisk sales beat estimates, but the story wasn't Ozempic
04:27am, Wednesday, 05'th Feb 2025
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn't its wildly popular weight-loss drugs.
Novo Nordisk's new CagriSema study to focus on dose escalation and trial length
04:11am, Wednesday, 05'th Feb 2025
Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose escalation and trial length to further show the drug's potential, after data in D
Novo Nordisk shares surge as Wegovy sales drive profit beat
04:01am, Wednesday, 05'th Feb 2025
Shares of Novo Nordisk climbed 4.5% on Wednesday after the Danish pharmaceutical giant reported a stronger-than-expected fourth-quarter net profit, driven by soaring demand for its obesity treatment,
Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns.
03:32am, Wednesday, 05'th Feb 2025
The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly's Zepbound and Mounjaro.
Novo Nordisk reports strong Q4 profits but warns of slower growth in 2025
03:06am, Wednesday, 05'th Feb 2025
Novo Nordisk (NYSE:NVO) posted a better-than-expected net profit of 28.23 billion Danish kroner ($3.98 billion) in the fourth quarter, beating analyst forecasts. The company's blockbuster Wegovy obes
Novo Nordisk to seek regulatory approval for CagriSema obesity drug early 2026
02:41am, Wednesday, 05'th Feb 2025
Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous e
Wegovy maker Novo Nordisk says surging growth driving emissions higher
02:09am, Wednesday, 05'th Feb 2025
Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of blockbuster obesity drug Wegovy.
Novo Nordisk posts net profit beat as Wegovy sales jump 107% in fourth quarter
01:44am, Wednesday, 05'th Feb 2025
Novo Nordisk posts net profit beat as Wegovy sales jump 107% in fourth quarter
Novo Nordisk Q4 profit beats expectations, sees slower growth in 2025
01:38am, Wednesday, 05'th Feb 2025
Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted fourth-quarter operating profit above expectations as it forecast sales to grow at a slower pace in 2025 than last year.
Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
01:30am, Wednesday, 05'th Feb 2025
Bagsværd, 5 February 2025 - Financial report for the period 1 January 2024 to 31 December 2024
Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - NVO
09:30pm, Tuesday, 04'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws
Shareholders With Losses In Novo Nordisk A/S Have Opportunity To Lead The Schall Law Firm In A Securities Fraud Case
08:45pm, Tuesday, 04'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo"
